文献速递糖尿病

利司那肽治疗现有降糖方案控制不佳的老年2型糖尿病患者:GetGoal-O随机试验

Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial.
PubMed 文献 · Diabetes Care · 2017-02-10

这项III期双盲随机安慰剂对照多中心试验纳入350例≥70岁、现有降糖方案控制不佳的2型糖尿病患者,在原有治疗基础上加用每日一次利司那肽20 μg或安慰剂治疗24周。利司那肽较安慰剂显著降低HbA1c(-0.57% vs +0.06%,P<0.0001)、2小时餐后血糖(-5.12 mmol/L vs -0.07 mmol/L,P<0.0001)和体重(-1.47 kg vs -0.16 kg,P<0.0001),安全性与其他利司那肽研究一致,低血糖报告率利司那肽组17.6% vs 安慰剂组10.3%。

要点

  • 利司那肽20 μg每日一次治疗24周,较安慰剂显著降低HbA1c(-0.57% vs +0.06%,P<0.0001)。
  • 利司那肽较安慰剂显著降低2小时餐后血糖(-5.12 mmol/L vs -0.07 mmol/L,P<0.0001)和体重(-1.47 kg vs -0.16 kg,P<0.0001)。
  • 低血糖报告率利司那肽组17.6% vs 安慰剂组10.3%,安全性与其他利司那肽研究一致。

核心结论

  • 在现有降糖方案控制不佳的非衰弱老年2型糖尿病患者中,利司那肽在降低HbA1c和针对餐后高血糖方面优于安慰剂,未发现非预期安全性问题。

研究设计与样本

  • III期、双盲、随机、安慰剂对照、两臂、平行组、多中心试验,患者年龄≥70岁,随机接受每日一次早餐前利司那肽20 μg或安慰剂,联合原有降糖治疗(包括胰岛素)24周。
  • 排除有营养不良风险或中度至重度认知障碍的患者,共随机350例患者。

主要发现

  • HbA1c从基线至第24周,利司那肽组下降0.57%(6.2 mmol/mol),安慰剂组上升0.06%(0.7 mmol/mol),P<0.0001。
  • 2小时餐后血糖平均降幅利司那肽组为5.12 mmol/L,安慰剂组为0.07 mmol/L,P<0.0001。
  • 体重降幅利司那肽组为1.47 kg,安慰剂组为0.16 kg,P<0.0001。
  • 低血糖报告率利司那肽组为17.6%,安慰剂组为10.3%。
  • 利司那肽在该老年人群中的安全性特征(包括恶心和呕吐发生率)与其他利司那肽研究一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and safety of lixisenatide versus placebo on glycemic control in older patients with type 2 diabetes uncontrolled on their current antidiabetic treatment. RESEARCH DESIGN AND METHODS: In this phase III, double-blind, randomized, placebo-controlled, two-arm, parallel-group, multicenter trial, patients aged ≥70 years were randomized to receive once-daily lixisenatide 20 μg or placebo before breakfast concomitantly with their existing antidiabetic therapy (including insulin) for 24 weeks. Patients at risk for malnutrition or with moderate to severe cognitive impairment were excluded. The primary end point was absolute change in HbA1c from baseline to week 24. Secondary end points included change from baseline to week 24 in 2-h postprandial plasma glucose (PPG) and body weight. RESULTS: A total of 350 patients were randomized. HbA1c decreased substantially with lixisenatide (-0.57% [6.2 mmol/mol]) compared with placebo (+0.06% [0.7 mmol/mol]) from baseline to week 24 (P < 0.0001). Mean reduction in 2-h PPG was significantly greater with lixisenatide (-5.12 mmol/L) than with placebo (-0.07 mmol/L; P < 0.0001). A greater decrease in body weight was observed with lixisenatide (-1.47 kg) versus placebo (-0.16 kg; P < 0.0001). The safety profile of lixisenatide in this older population, including rates of nausea and vomiting, was consistent with that observed in other lixisenatide studies. Hypoglycemia was reported in 17.6% of patients with lixisenatide versus 10.3% with placebo. CONCLUSIONS: In nonfrail older patients uncontrolled on their current antidiabetic treatment, lixisenatide was superior to placebo in HbA1c reduction and in targeting postprandial hyperglycemia, with no unexpected safety findings.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Meneilly GS, Roy-Duval C, Alawi H, et al. Lixisenatide Therapy in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Antidiabetic Treatment: The GetGoal-O Randomized Trial. Diabetes Care. 2017. PMID: 28188240. doi:10.2337/dc16-2143

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。